AHA 2018 In Japanese patients aged ≥75 years with elevated LDL-c levels, ezetimibe results in prevention of atherosclerotic CV events, as shown in the EWTOPIA75 randomized trial.
AHA 2018 The Federal physical activity guidance stresses the importance and feasibility of incorporating more physical activity in daily life for all ages, and highlights all preventive benefits of physical activity.
AHA 2018 The VITAL trial tested the effect of vitamin D and/or omega-3 supplementation on CVD and cancer outcomes in a large primary prevention cohort, and found few benefits of either product.
AHA 2018 Yoga-CaRe is safe, feasible and significantly improves quality of life and return to pre-infarct daily activities. The per-protocol analysis suggests that yoga does lower CV events in adherent patients.
AHA 2018 In the randomized REDUCE-IT trial, daily treatment with icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowered CV events in primary and secondary prevention of hypertriglyceridemic patients.
AHA 2018 The updated cholesterol guidelines help physicians to personalize treatment based on risk assessment, and now include CAC measurement to guide treatment decisions in certain patients.
In an observational study, antihypertensive treatment was not associated with reduced mortality or rates of CVD in low-risk patients with mild hypertension.
In this randomized trial, the long-term intensive PREDIMED-Plus lifestyle intervention resulted in weight loss and reduced CV risk in overweight/obese adults with metabolic syndrome, compared to standard care.
In a large cohort study, pulse pressure stress index (P2SI) was inversely associated with risk of HF and all-cause mortality in individuals with suspected CAD.
Several measurements in a small sample of healthy individuals suggest that prolonged sitting has a negative impact on peripheral and central vascular health, particularly on leg vasodilatory function and aortic pulse wave velocity.
A retrospective study showed better SBP during antihypertensive therapy and lower risk of antihypertensive treatment failure in hypertensive patients with good oral health, as compared with those with periodontitis.
In a cohort study, use of β-blockers in the first trimester was not associated with increased risk of congenital overall or cardiac malformations.